Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
T-Rex 2x Inverse Tesla Daily Target ETF
TSLZ
US Stock MarketDetailed Quotes
AVIR Atea Pharmaceuticals
- 2.960
- +0.070+2.42%
Close Apr 28 16:00 ET
253.15MMarket Cap-1.48P/E (TTM)
2.990High2.870Low220.75KVolume2.870Open2.890Pre Close652.80KTurnover0.33%Turnover RatioLossP/E (Static)85.53MShares4.14552wk High0.58P/B196.41MFloat Cap2.60052wk Low--Dividend TTM66.36MShs Float94.174Historical High--Div YieldTTM4.15%Amplitude2.600Historical Low2.957Avg Price1Lot Size
About Atea Pharmaceuticals Company
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Company Profile
SymbolAVIR
Company NameAtea Pharmaceuticals
Listing DateOct 30, 2020
Issue Price24.00
Founded2012
CEODr. Jean-Pierre Sommadossi,PhD
MarketNASDAQ
Employees56
Fiscal Year Ends12-31
Address225 Franklin Street,Suite 2100
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02110
Phone1-857-284-8891
Websitehttp://www.ateapharma.com
Company Executives
- Name
- Position
- Salary
- Dr. Jean-Pierre Sommadossi,PhD
- President, Chief Executive Officer and Chairman of the Board
- 5.93M
- Andrea J. Corcoran
- Chief Financial Officer, Executive Vice President, Legal and Secretary
- 1.96M
- Wayne Foster
- Executive Vice President, Finance and Chief Accounting Officer
- 1.52M
- John Vavricka
- Chief Commercial Officer
- --
- Dr. Maria Arantxa Horga, M.D.
- Chief Medical Officer
- 1.85M
- Dr. Janet Hammond, M.D.,PhD
- Chief Development Officer
- 2.11M
- Arthur Kirsch
- Director
- --
- Dr. Howard Berman, PhD
- Director
- --
- Barbara G. Duncan
- Independent Director
- 332.10K
- Jerome M. Ada M.D.
- Independent Director
- 442.10K
- Franklin M. Berger, C.F.A.
- Lead Independent Director
- 357.10K
- Bruno Lucidi
- Independent Director
- 324.60K
- Dr. Polly A. Murphy, D.V.M.,PhD
- Independent Director
- 327.10K
- Dr. Bruce Polsky, M.D.
- Independent Director
- 324.60K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now